The Dual Effects of B Cell Depletion on Antigen-Specific T Cells in BDC2.5NOD Mice

Yufei Xiang, Jian Peng, Ningwen Tai, Changyun Hu, Zhiguang Zhou, F. Susan Wong and Li Wen

*J Immunol* 2012; 188:4747-4758; Prepublished online 4 April 2012;
doi: 10.4049/jimmunol.1103055
http://www.jimmunol.org/content/188/10/4747

---

**Supplementary Material**  
http://www.jimmunol.org/content/suppl/2012/04/04/jimmunol.110305.5.DC1

**References**  
This article cites 26 articles, 13 of which you can access for free at:  
http://www.jimmunol.org/content/188/10/4747.full#ref-list-1

**Subscription**  
Information about subscribing to *The Journal of Immunology* is online at:  
http://jimmunol.org/subscription

**Permissions**  
Submit copyright permission requests at:  
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**  
Receive free email-alerts when new articles cite this article. Sign up at:  
http://jimmunol.org/alerts
The Dual Effects of B Cell Depletion on Antigen-Specific T Cells in BDC2.5NOD Mice

Yufei Xiang,*†‡ Jian Peng,*‡† Ningwen Tai,*‡† Changyun Hu,* Zhiguang Zhou,†‡ F. Susan Wong,*§ and Li Wen*

B cells play a critical role in the pathogenesis of autoimmune diabetes. To investigate the mechanisms by which B cell depletion therapy attenuates islet β cell loss and particularly to examine the effect of B cells on both diabetogenic and regulatory Ag-specific T cells, we generated a transgenic BDC2.5NOD mouse expressing human CD20 on B cells. This allowed us to deplete B cells for defined time periods and investigate the effect of B cell depletion on Ag-specific BDC2.5 T cells. We depleted B cells with anti-human CD20 Ab using a multiple injection protocol. We studied two time points, before and after B cell regeneration, to examine the effect on BDC2.5 T cell phenotype and functions that included antigenic response, cytokine profile, diabetogenicity, and suppressive function of regulatory T (Treg) cells. We found unexpectedly that B cell depletion induced transient aggressive behavior in BDC2.5 diabetogenic T cells and reduction in Treg cell number and function during the depletion period. However, after B cell reconstitution, we found that more regenerated B cells, particularly in the CD1d+ fraction, expressed immune regulatory function. Our results suggest that the regenerated B cells are likely to be responsible for the therapeutic effect after B cell depletion. Our preclinical study also provides direct evidence that B cells regulate both pathogenic and Treg cell function, and this knowledge could explain the increased T cell responses to islet Ag after rituximab therapy in diabetic patients in a recent report and will be useful in design of future clinical protocols.


Received for publication October 24, 2011. Accepted for publication March 2, 2012.

This work was supported by the Juvenile Diabetes Research Foundation International (Grants 1-2007-586 and 4-2007-1059) and the Diabetes Endocrinology Research Center transgenic and animal core (National Institute of Diabetes and Digestive and Kidney Diseases). Y.X. was a recipient of a Ph.D. fellowship from the China Scholarship Council (2008637071).

J.P. and N.T. contributed equally.

The mechanisms underlying the effect of B cell depletion on diabetogenic T cells are largely unknown. Furthermore, it is puzzling why patients with T1D who responded better to rituximab...
treatment have shown stronger T cell responses in vitro to islet autoantigen(s) (8). To facilitate our understanding of this paradoxical phenomenon and to further investigate the effect of B cell depletion on Ag-specific diabeticogenic and regulatory CD4 T cells, we generated hCD20/BDC2.5 double Tg mice. Using this double Tg NOD mouse model system, we found that B cells have a basal role in regulating diabeticogenic T cells, because prolonged depletion of B cells increases pathogenicity of diabeticogenic CD4 T cells. However, protective regulation is increased following B cell regeneration, which suggests that the major immune regulatory effect comes from the regeneration phase of the treatment.

**Materials and Methods**

**Mice**

To generate hCD20-BDC2.5 Tg NOD mice, we bred our hCD20NOD mice (4) with BDC2.5 NOD mice purchased from The Jackson Laboratory. Foxp3 reporter (Fir) mice were generated as described previously (13) and provided by R. Flavell (Yale University, New Haven, CT). Fir mice were backcrossed onto the NOD background for >10 generations, then bred with hCD20-BDC2.5NOD mice to obtain hCD20-BDC2.5-Fir NOD mice. NOD/Caj and NOD.SCID mice have been maintained at Yale University for >20 y. All the mice were kept in specific pathogen-free conditions in a 12-h dark/light cycle and housed in individually ventilated filter cages with autoclaved food. All studies were approved by the Institutional Animal Care and Use Committee of Yale University.

**Abs and reagents**

All fluorochrome-conjugated purified mAbs used in this study were purchased from eBioscience or BioLegend. The mAb hybridoma supernatants were provided by the late Charles Janeway, Jr. (Yale University). Anti-hCD20 mAb 2H7 (14), recognizing the same epitope as rituximab, was affinity purified by BioXCell from the hybridoma cell line 2H7 (kindly provided by E.A. Clark, University of Washington), Control IgG used in the in vivo studies was purchased from Rockland. Magnetic beads conjugated with goat anti-mouse IgG and IgM and goat anti-rat IgG were purchased from Qiagen. Bruff’s medium and heat-inactivated FCS were purchased from Invitrogen and Gemini, respectively. The BDC2.5 mimotope peptide (RTRPLWVRME) was synthesized at the Keck facility at Yale University.

**B cell depletion protocol**

HCD20-BDC2.5 Tg NOD mice were treated with four doses of anti-hCD20 (2H7) or control IgG, weekly for the first two doses and once every other week for the remaining three doses. This protocol was modified from the protocol for the rituximab clinical trial in T1D patients (four weekly doses of anti-CD20 treatment) (8).

**Cell purification**

Whenever possible, cell purification was performed by negative selection. B cells were purified by removing CD4+ (clone GK1.5), CD8+ T cells (clone T1B105), and macrophages (F4/80) using mAb hybridoma supernatants, followed by magnetic bead (conjugated with anti–Rat-IgG) separation. CD4 T cells were purified by removing CD8+ T cells (mAb T1B105), B cells (anti-mouse Igs), and 1-Ag7 MHC class II+ cells (mAb I0.2.16) using mAb hybridoma supernatants and magnetic bead separation. The purity of the cells was routinely ≥90%, analyzed by FACS. For in vivo experiments, cells were purified by flow cytometric sorting using positive selection.

**Proliferation assays**

For BDC2.5 T cell proliferation assays, purified CD4+ BDC2.5 T cells from 2H7- or mouse IgG (mIgG)-treated hCD20-BDC2.5NOD mice were cocultured (10^5/well) with irradiated APCs (5 × 10^4/well) from 6-wk-old NOD mice with or without BDC2.5 mimotope peptide. For tests of Treg cell function, purified CD4^+CD25^+ BDC2.5 T effector (Tem) cells (10^4) from spleen, MLN, and PLN when the mice shown in (A) were terminated (10 d after the last Ab injection).

**FIGURE 1.** B cell depletion in hCD20BDC2.5 NOD mice. (A) B cell profile in peripheral blood after depletion of B cells. After the first injection (500 μg), 250 μg was administered a week later, followed by three additional injections at 2-wk intervals. After removing erythrocytes, peripheral blood cells were costained with anti-CD19 and anti-B220 and analyzed by flow cytometry prior to the next injection. B cell (B220^+CD19^-) percentage in total lymphocytes is shown at different time points. Mean values ± SEM of six to eight mice are presented. (B) B cell depletion in different lymphoid organs. HCD20-BDC2.5NOD mice were treated with 2H7 (upper panel) or mIgG (lower panel). (B) shows representative depletion profiles of B cells (IgM^-B220^-) from spleen, MLN, and PLN when the mice shown in (A) were terminated (10 d after the last Ab injection).
well) were cocultured with irradiated Foxp3+ Treg cells (5 x 10^6/well) from 2H7- or mlgG-treated hCD20-BDC2.5NOD mice. For B cell suppression tests, purified CD4+ BDC2.5 T cells (10^6/well) were cultured with (3 x 10^6/well) irradiated B cells (CD19^+CD22^+), regulatory B cell (Breg) (CD1d^+CD19^+CD22^+), or non-Breg cells (CD1d^+CD19^+CD22^+) from NOD mice. Proliferation of BDC2.5 T cells was assessed by [3H]thymidine incorporation during the last 14–18 h of the 3-d culture. Cell proliferation is presented either by cpm or as stimulation index calculated as [3H]thymidine incorporation during the last 14–18 h of the 3-d culture. Cell proliferation was confirmed by blood glucose measurement (daily for glycosuria for the first 3 wk and then twice a week. Diabetes was mouse). The mice were screened for diabetes development with Diastix (CD1d^+CD19^+B220^+), or non-Breg cells (CD1d^+CD19^+B220^+), or mIgG were i.v. injected (10^7/mouse) into hCD20-BDC2.5NOD mice that had been treated with 2H7 or mlgG. Recipient mice were sacrificed 5 d later, and lymphocytes from spleen, mesenteric lymph nodes (MLN), and pancreatic lymph nodes (PLN) were harvested and stained with fluorochrome-conjugated mAbs against surface markers and intracellular cytokines.

Adoptive transfer experiments

Purified BDC2.5 T cells from hCD20-BDC2.5NOD mice treated with 2H7 or mlgG were i.v. injected into 6- to 8-wk-old NOD.SCID mice (10^6/mouse). The mice were screened for diabetes development with Diastix daily for glycosuria for the first 3 wk and then twice a week. Diabetes was confirmed by blood glucose measurement (250 mg/dl) with a glucose meter (One Touch; Johnson and Johnson). For cotransfer experiments, purified CD4+ BDC2.5 T cells (10^6/mouse) were cocultured with purified B cells (total B cells or B cell subsets) into NOD.SCID mice.

Luminex assay to determine cytokines

Plasma cytokines were detected using Luminex beads, following the manufacturer’s protocol (Bio-Rad). Plates were read in a Luminex reader (Bio-Rad 200).

Statistics

Statistical analysis was performed using GraphPad Prism software. The incidence of diabetes was compared using the log-rank test. Mean values for flow cytometric analysis were compared by unpaired Student t tests.

Results

hCD20/BDC2.5NOD mice and B cell depletion

BDC2.5/NOD mice develop a very low incidence of spontaneous diabetes, although BDC2.5 cells used ex vivo are highly diabetogenic (9, 10). Introducing the hCD20 transgene did not change the phenotype, nor did it affect the function of BDC2.5 T cells (Supplemental Fig. 1). Injection of mouse IgG also did not have any noticeable effect in the hCD20-BDC2.5NOD, BDC2.5/NOD, and NOD mice used in this study (data not shown). To study the effect of B cells on diabetogenic BDC2.5 CD4+ T cells, we

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Tissue</th>
<th>2H7</th>
<th>mlgG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cells (x 10^6)</td>
<td>SPL</td>
<td>37.88 ± 8.11</td>
<td>83.63 ± 3.68</td>
</tr>
<tr>
<td></td>
<td>MLN</td>
<td>2.78 ± 0.76</td>
<td>7.830 ± 0.400</td>
</tr>
<tr>
<td></td>
<td>PLN</td>
<td>1.03 ± 4.24</td>
<td>4.73 ± 8.756</td>
</tr>
<tr>
<td>Vβ84/CD4+ T cells (x 10^6)</td>
<td>SPL</td>
<td>17.61 ± 3.77</td>
<td>22.58 ± 0.99</td>
</tr>
<tr>
<td></td>
<td>MLN</td>
<td>2.67 ± 0.12</td>
<td>3.61 ± 0.181</td>
</tr>
<tr>
<td></td>
<td>PLN</td>
<td>0.75 ± 0.31</td>
<td>1.84 ± 0.34</td>
</tr>
<tr>
<td>B220^+IgM+ B cells (x 10^6)</td>
<td>SPL</td>
<td>6.42 ± 1.38</td>
<td>49.34 ± 2.17</td>
</tr>
<tr>
<td></td>
<td>MLN</td>
<td>0.06 ± 0.003</td>
<td>1.30 ± 0.065</td>
</tr>
</tbody>
</table>

Mice were sacrificed after B cell depletion. Values (mean ± SEM) indicate cell number (x 10^6) present in each tissue (n = 5/group).

RESULTS

Enhanced proliferative responses of BDC2.5 diabetogenic T cells soon after B cell depletion

Our previous study was mostly focused on the regenerated B cells and the effect on polyclonal pathogenic and Treg cells, long after B cell depletion (4). However, it was not clear what the immediate effect of B cell depletion was on Ag-specific T cells. To investigate the function of BDC2.5 T cells following B cell depletion, but before B cell regeneration, we tested their response to the cognate Ag in vitro. As shown in Fig. 2A, purified BDC2.5 T cells from

FIGURE 2. Enhanced proliferation of BDC2.5 diabetogenic T cells after B cell depletion. (A) BDC2.5 T cell proliferation in vitro. Purified BDC2.5 CD4+ T cells from treated hCD20-BDC2.5NOD mice (n = 5) cocultured with irradiated NOD APCs in the presence or absence of BDC2.5 mimotope. Cell proliferation was shown as stimulation index = [3H]thymidine incorporation (cpm) in the presence of mimotope/[3H]thymidine incorporation in the absence of mimotope stimulation. The average [3H]thymidine incorporation (cpm) without mimotope stimulation was 513.3 ± 72.76. Similar results were obtained from three independent experiments. (B) Proliferation of BDC2.5 T cells in vivo. hCD20NOD mice were treated with 2H7 or mlgG as described in Materials and Methods. CFSE-labeled BDC2.5 CD4+ T cells (10^6) were injected into treated mice. Spleen and PLN were harvested from recipient mice 5 d later, and cell proliferation was determined by flow cytometric detection of CFSE dilution. Numbers indicate relative percentage of CFSE-diluted BDC2.5 T cells in PLN. (C) Summary of proliferation of BDC2.5 T cells in vivo. Numbers indicate the percentage of proliferated cells in total CFSE-labeled BDC2.5 T cells (n = 3/group). Similar results were obtained from two independent experiments.
B cell-depleted hCD20-BDC2.5NOD mice responded more strongly to mimotope antigenic peptide than BDC2.5 CD4+ T cells from control IgG-treated mice (p = 0.03; Fig. 2A). This was further confirmed using CFSE-labeled purified BDC2.5 CD4+ T cells from BDC2.5NOD mice injected into hCD20NOD hosts that had been treated with anti-CD20 or control IgG (Fig. 2B, 2C). Our results suggest that BDC2.5 T cells were more responsive to their cognate Ag early after B cell depletion, before B cell repopulation.

**BDC2.5 T cells from newly B cell-depleted mice accelerate diabetes in adoptive transfer**

To further investigate the function of BDC2.5 diabetogenic T cells related to B cell depletion, and also to confirm that the in vivo results presented in Fig. 2 were not due to homeostatic proliferation, we performed adoptive transfer experiments using purified splenic BDC2.5 CD4+ T cells from B cell-depleted or control IgG-treated hCD20-BDC2.5NOD mice. We found that BDC2.5 cells from newly B cell-depleted donors, whereas the mice remained B cell-depleted, more potently induced diabetes in NOD.SCID mice compared with cells from control IgG-treated donors (p = 0.031; Fig. 3A). To check for possible homeostatic proliferation, we harvested the BDC2.5 cells from all the NOD.SCID recipients when the mice were terminated. We did not find more BDC2.5 cells from NOD.SCID mice that were transferred with BDC2.5 cells from B cell-depleted donor mice compared with those that had been treated with control IgG. The number of BDC2.5 cells recovered from the spleen and lymph nodes was very similar in all the recipients (data not shown). In addition, we purified CD4+ T cells from the islets of B cell-depleted or control hCD20-BDC2.5 mice and transferred these cells to NOD.SCID recipients. Consistent with the earlier results, islet-infiltrating BDC2.5 T cells from B cell-depleted donor mice also induced more rapid diabetes onset (100% in <20 d) in the NOD.SCID recipients compared with the mice transferred with BDC2.5 T cells from control IgG-treated donors (100% by 80 d; Fig. 3B).

In line with our in vivo results, BDC2.5 T cells extracted from NOD.SCID recipients given BDC2.5 T cells from B cell-depleted hCD20-BDC2.5 donors expressed a stronger response to the antigenic peptide than cells retrieved from NOD.SCID recipients treated with BDC2.5 T cells from control-treated hCD20-BDC2.5NOD mice (Fig. 3C). Thus, our results support the notion that B cell depletion could lead to enhanced potency of proliferation and diabetes induction by diabetogenic CD4+ T cells.

**More proinflammatory cytokines are produced early after B cell depletion**

To further investigate the function of BDC2.5 diabetogenic T cells after B cell depletion, we examined the inflammatory cytokine profile of BDC2.5 T cells from spleen, MLN, and PLN of 2H7 or control IgG-treated hCD20-BDC2.5 mice (Fig. 4A, spleen). B cell depletion resulted in a significant increase in TNF-α production by CD4+ BDC2.5 T cells from spleen and MLN but not from PLN (Fig. 4B). To confirm this finding, we also measured multiple circulating cytokines in the plasma samples from anti-CD20 or control IgG-treated mice. Cytokine profiles in the plasma also showed that there were more proinflammatory cytokines that in...
FIGURE 4. BDC2.5 T cells produce more inflammatory cytokines after B cell depletion. HCD20-BDC2.5NOD mice were sacrificed after 2H7 or mIgG treatment. Spleen, MLN, and PLN cells were stimulated with BDC2.5 mimotope (10 ng/ml) overnight, followed by intracellular staining for cytokines. (A) Representative dot plots for inflammatory cytokine production by splenic BDC2.5 T cells after 2H7 and mIgG treatment. (B) Summary of percentage of inflammatory cytokine-producing BDC2.5 T cells (TNF-α+CD4+, IFN-γ+CD4+, and IL-17+CD4+) on gated CD4+ T cells (mean ± SEM; n = 4) in B cell-depleted (○) or control IgG (●)-treated hCD20-BDC2.5NOD mice. Similar results were obtained from three independent experiments. (C) Circulating plasma cytokines including TNF-α, IL-6, IL-12p40, IL-17, and IFN-γ were measured by Luminex assay from B cell-depleted and control IgG-treated mice (n > 12/group). All the numbers above the lines in (B) and (C) are p values.
B cell depletion modifies the number and function of Treg cells

Our previous study showed that Treg cells were increased long after B cell depletion (4). However, the immediate effect of B cell depletion on Treg cells was not known. In this study, we found that B cell depletion resulted in a significant, maintained reduction of Ag-specific BDC2.5 Treg cells, during the period of B cell depletion, compared with control IgG-treated mice, in peripheral blood (p < 0.05; Fig. 5A), MLN (p = 0.0026; Fig. 5B), and PLN (p = 0.0006; Fig. 5B). To explore whether there was enhanced Ag-specific Treg cell migration to islets, contributing to the reduction of Treg cells in other lymphoid organs, we analyzed islet-infiltrating lymphocytes from 2H7- or control IgG-treated hCD20-BDC2.5NOD mice by flow cytometry. However, we found that concordant with fewer BDC2.5 Treg cells in other lymphoid tissues, there was also a decrease of BDC2.5 Treg cells in islets of 2H7-treated mice (Fig. 5C). To study whether B cell depletion affected the function of the Treg cells, we bred hCD20-BDC2.5NOD mice with Foxp3 RFP reporter (Fir) NOD mice to obtain triple Tg hCD20-BDC2.5-FirNOD mice. We treated hCD20-BDC2.5-FirNOD mice with anti-CD20 or control IgG and FACS-sorted BDC2.5 (Vb4+) Fir+ (Foxp3+) Treg cells and Vb4+ CD25+ Fir+ Teff cells. To our surprise, Treg cells from islets of B cell-depleted donor mice could not suppress the proliferation of Treg cells in response to antigenic peptide (BDC2.5 mimotope) as effectively as their counterparts from control IgG-treated mice (data not shown). To test whether this was due to resistance of Teff cells to regulation by Treg cells (15), we performed cross-culture experiments in which Teff cells were from 2H7- or IgG-treated group together with irradiated APCs in the presence of BDC2.5 mimotope. Interestingly, we found that CD1d+ B cells (B220+CD19+CD5low+) from either the 2H7- or mIgG-treated group together with irradiated APCs in the presence of BDC2.5 mimotope. Surprisingly, we found that CD1d+ B (CD19+B220+) cells suppressed BDC2.5 T cell proliferation in vitro, whereas CD1d+ B cells enhanced the BDC2.5 T cell response (Fig. 7B). To test the function of these B cells in vivo, we transferred BDC2.5 T cells (0.5 × 10^6) with purified CD1d+ B or CD1d+ B cells (1.5 × 10^6) from either 2H7- or mIgG-treated mice, after B cell repopulation, to NOD.Scid recipients. In line with the in vitro data, we found that cotransfer of BDC2.5 T cells with CD1d+ B cells from 2H7 as well as mIgG-treated mice accelerated diabetes development, whereas cotransfer with CD1d− B cells from either the mIgG- or 2H7-treated groups reduced diabetes development (Fig. 7C). All the recipients cotransferred with BDC2.5 T cells and CD1d+ B cells developed diabetes by 10 d, whereas it took 20 d for the recipients transferred with only BDC2.5 T cells to develop diabetes. Furthermore, 30% of recipients cotransferred with BDC2.5 T cells and CD1d+ B cells remained diabetes free at the time the experiment was terminated (p = 0.048; Fig. 7C).

As depletion of B cells led to an increase in pathogenicity of diabetogenic BDC2.5 cells when tested soon after depletion was completed, but before regeneration of B cells, this suggested that there is an endogenous subset of B cells that has a suppressive effect on diabetogenic CD4 T cells, although this is not sufficient to prevent NOD mice from diabetes in normal circumstances. To investigate whether CD1d+ and CD1d− B cells from normal NOD mice could regulate BDC2.5 T cells, we divided the two populations from unmanipulated NOD mice. The sorted B cells (1.5 × 10^6) were cotransferred with purified BDC2.5 T cells (0.5 × 10^6) into NOD.Scid recipients. CD1d+ B cells from NOD mice did not show much effect on diabetes development (p = 0.88; Fig.
7D); however, cotransfer of CD1d− B cells from NOD mice with BDC2.5 cells led to a significant reduction in diabetes development (p = 0.04; Fig. 7D), similar to the results using regenerated CD1d− B cells from 2H7-treated mice (Fig. 7C) and the in vitro results shown in Fig. 7B. Yanaba et al. (19) reported that CD1d+CD5+ B cells were potent Breg cells. To examine whether CD5 plays a role in our findings described above, we sorted CD1d+CD5− and CD1d− CD5+ B cells (gated on B220+CD19+) from splenocytes of normal NOD mice. In contrast to the results presented in Fig. 7B, where sorted CD1d− CD5low− B cells were used, CD1d+CD5+ B cells suppressed the proliferation of BDC2.5 T cells (Fig. 8A). However, in line with the results showed in Fig. 7B, CD1d− B cells, although CD5+, showed stronger suppression of the antigenic response by BDC2.5 T cells (Fig. 8A). We also examined IL-10 production by these two B cell subsets. Consistent with the report by Yanaba et al. (19), CD1d+CD5+ B cells produced a large amount of IL-10, whereas CD1d− CD5+ B cells did not (Fig. 8B). Interestingly, the suppression mediated by either CD1d+CD5+ or CD1d− CD5+ B cells was not dependent on IL-10 as IL-10−deficient CD1d+ CD5+ or CD1d− CD5+ B cells were still strongly suppressive (Fig. 8C). Next, we tested whether the suppression was cell–cell contact dependent. We repeated the above suppression assay but separated purified CD1d+CD5+ or CD1d− CD5+ B cells from BDC2.5

FIGURE 5. B cell depletion reduces BDC2.5 Treg number and function. (A) Foxp3+ Treg cells from PBMC were analyzed by flow cytometry following treatment of hCD20-BDC2.5NOD mice with 2H7 or mlG. The percentage of BDC2.5 Treg cells decreased in 2H7-treated mice (n = 6–8 mice/group; p < 0.05). (B) Percentages of Treg in BDC2.5 T cells in different lymphoid organs were variable. Representative dot plots show the percentage of BDC2.5 Treg (Foxp3+CD25highlow) cells. The bar charts show the pooled data from at least six mice per group (mean ± SEM). (C) BDC2.5 Treg in islets from 2H7- or mlG-treated hCD20-BDC2.5NOD mice. After islet isolation, the islet cells were dispersed, and infiltrating cells were stained with the corresponding mAbs and analyzed by flow cytometry. There were fewer infiltrating Treg cells in islets after B cell depletion. Dot plots are shown after gating on CD4+ cells. At least two mice were pooled for islet isolation. Experiments were performed three times and summarized in the bar graphs on the right. (D) Cross-suppression assay. Foxp3+ BDC2.5 Treg cells were sorted from 2H7- or mlG-treated hCD20-BDC2.5-FirNOD mice and used as Treg (Foxp3+) and Teff cells (Fir−CD25−CD4+) were also sorted from 2H7- or mlG-treated hCD20-BDC2.5-FirNOD mice. As indicated in (D), the cross-suppression assay was performed by coculturing Teff cells from 2H7-treated mice with Treg cells from mouse IgG-treated mice or Teff cells from IgG-treated mice with Treg cells from 2H7-treated mice. Cocultures of 2H7-treated Teff and Treg cells or IgG-treated Teff and Treg cells were used as controls. A cell ratio of 2:1 (Teff:Treg) was used in the cocultures. Proliferation is shown as stimulation index. Treg cells from 2H7-treated mice do not suppress Teff cell proliferation as effectively as Treg cells from mlG-treated mice. The average [3H]thymidine incorporation in the absence of mimotope = 74.65 ± 13.48 cpm. Similar results were obtained from three independent experiments.
FIGURE 6. Regenerated B cells affect T cell phenotype and function. HCD20-BDC2.5 NOD mice were sacrificed 10 wk after the last injection of 2H7 or mlgG. (A) Bar graphs indicate the percentage of Treg cells (Foxp3\(^+\)CD4\(^+\)) in gated CD4\(^+\) T cells in different lymphoid organs (mean ± SEM; n = 4–5). Similar results were obtained from two independent experiments. (B) Treg cells in islets after B cell regeneration. Islets were isolated from hCD20-BDC2.5 NOD mice following B cell reconstitution after B cell depletion. Treg cells (Foxp3\(^+\)CD25\(^{high+low}\)) are shown as percentage of BDC2.5 T cells (CD4\(^+\)V\(\beta\)4\(^+\)). Four mice were pooled for islet isolation. (C) Treg functional recovery with B cell reconstitution. HCD20-BDC2.5-Fir NOD mice were sacrificed 2 mo after the end of the 2H7 or mlgG treatment. Fir\(^+\) T cells were sorted and used as Treg cells (Foxp3\(^+\)) in coculture with Teff cells (Fir\(^-\)CD25\(^-\)CD4\(^+\)) and irradiated splenic APC from normal NOD mice. \([3H]\)Thymidine incorporation is shown as stimulation index. Treg cells from 2H7-treated mice after B cell reconstitution show increased suppression of Teff cells compared with the control group. Average \([3H]\)thymidine incorporation without mimotope stimulation = 103.25 ± 14.58. Similar results were obtained from at least three independent experiments. (D) Circulating plasma cytokine (Figure legend continues)
T cells within the culture by Transwell. As shown in Fig. 8D, the suppression was completely abolished without cell–cell contact.

Discussion

We and others showed previously that B cell depletion could prevent and reverse diabetes development in NOD mice (4–7). Importantly, results from anti-CD20 (rituximab) clinical trial revealed a similar outcome (3). However, it is interesting that patients who responded better to the therapy showed stronger T cell responses to islet Ags in vitro (8). To investigate this paradoxical phenomenon and the mechanism behind it, we generated hCD20-BDC2.5NOD mice to examine the effects of B cell depletion specifically on both Ag-specific pathogenic and regulatory CD4 T cells in T1D. The introduction of the hCD20 transgene, of itself, did not alter the phenotype or functions of BDC2.5 T cells. However, we found that during the B cell depletion period, before regeneration of B cells, islet Ag-specific BDC2.5 T cells responded to the Ag more robustly in vitro and more aggressively induced diabetes in vivo, compared with non-B cell–depleted control mice. During this time, more inflammatory cytokines were produced, including TNF-α, IL-6, and IL-12p40, and there was also a reduction in Foxp3+ Treg cell number and suppressive function in the mice, whereas B cells were depleted.

Profiles including TNF-α, IL-6, IFN-γ, and IL-17 were measured by Luminex from B cell reconstituted mice and control mice (n = 6–9). (E) Adoptive transfer of diabetes by BDC2.5 T cells. NOD.SCID mice were injected i.v. with 10⁶ purified splenic BDC2.5 T cells taken after B cell reconstitution from 2H7- or mIgG-treated hCD20-BDC2.5NOD mice (10 wk after the end of treatment). Diabetes development was delayed and reduced up to the first 50 d in the recipients given BDC2.5 T cells from 2H7-treated donor mice; however, there was no statistical difference, n = 9/group; p = 0.97.

FIGURE 7. CD1d+B cells are more protective than CD1d− B cells. HCD20-BDC2.5NOD mice were sacrificed 2 mo after the last treatment. (A) Representative dot plots (top panels) showing regenerated B cells (gated on CD19+) from 2H7- or mIgG-treated hCD20-BDC2.5NOD mice as determined by immunofluorescent staining with CD1d, CD19, and B220. At least three mice per group were used for each experiment, and the experiments were performed three times as summarized in the lower panels. (B) Purified BDC2.5 T cells were cocultured with three times the number of sorted CD1d+ B cells (CD19+B220+) or CD1d− B cells (irradiated after sorting) in the presence of 10 ng/ml mimotope. Stimulation index was calculated as described earlier. Background cpm in the absence of mimotope was 80.17 ± 7.1. P = 0.0012 for three groups overall. Similar results were obtained from three independent experiments. (C) Purified BDC2.5 T cells (0.5 × 10⁶) were cotransferred with sorted CD1d+ or CD1d− B cells (1.5 × 10⁵) taken from 2H7-treated hCD20-BDC2.5NOD mice in the B cell regeneration phase (2 mo after the treatment). Mice were screened daily for diabetes. Mice transfere with BDC2.5 B cells only (n = 6) were compared with mice transfere with BDC2.5 T cells together with CD1d+ 2H7-treated B cells (n = 10); p = 0.08. Mice transfere with BDC2.5 T cells together with CD1d+ 2H7-treated B cells were compared with mice transfere with BDC2.5 T cells together with CD1d− 2H7 B cells (n = 10); P = 0.048. (D) Purified BDC2.5 T cells (10⁶) with sorted CD1d+CD19+B220+ B cells or CD1d−CD19+B220+ B cells from 6-wk-old NOD mice were transferred (3 × 10⁵) into NOD.SCID recipient mice. For comparison between BDC2.5 T cells with or without CD1d+B cells, P = 0.04; for comparison of BDC2.5 T cells with or without CD1d−B cells, P = 0.88.
develop spontaneous diabetes even with continued B cell depletion (data not shown). However, after B cell regeneration, this enhanced inflammatory phenotype was controlled. The number and function of Treg cells were restored. Our results support, at least in part, the human studies showing that some patients had increased T cell responses to islet Ags 6 mo after anti-CD20 treatment, whereas these increased T cell responses were decreased at a later time point (12 mo) after the treatment (8). Thus, B cell depletion treatment has biphasic effects on Ag-specific diabetogenic and Treg cells, increasing pathogenicity of diabetogenic T cells and reducing Treg cells, whereas B cells are depleted, an effect that is reversed after B cell repopulation. Our results support a regulatory role for B cells in influencing T cell phenotype and function, and this is enhanced once B cell populations are restored after depletion.

The clinical trial results using rituximab to treat newly diagnosed patients with T1D showed that one course of short-term B cell depletion could delay β cell loss and preserve β cell function (3), as was also shown in the preclinical models of diabetes (4–7). Results from further prolonged follow up have indicated that significant differences in various parameters compared with control groups were less sustained (20). Furthermore, it is not clear why some patients with T1D showed stronger T cell responses in vitro to islet autoantigen(s) after rituximab treatment (8). Thus, understanding how the treatment affects diabetogenic T cells may provide an insight into how B cell treatment could be optimized. In our study, the use of the hCD20-BDC2.5 double Tg mouse allowed us to investigate the mechanisms underlying the effects of B cell depletion specifically on well-characterized, highly diabetogenic CD4 T cells both during the period of B cell depletion as well as after repopulation of B cells. Our results showing that during and soon after B cell depletion, diabetogenic BDC2.5 CD4 T cells became more inflammatory and aggressive. This was manifested by a more robust response to cognate Ag stimulation and accompanied by more proinflammatory cytokine production in vitro and in vivo, and the cells also caused more rapid diabetes when adoptively transferred to immunodeficient NOD.SCID mice. This was not due to homeostatic proliferation within the hCD20-BDC2.5 double Tg mouse, prior to harvesting the cells for adoptive transfer, as the number of BDC2.5 T cells was, in fact, reduced in hCD20-BDC2.5 hosts after B cell depletion. Interestingly, patients with T1D showed a transient decrease of T cells (CD4+ and CD8+) not long after anti-CD20 treatment (8). In addition, we also observed that Foxp3+ BDC2.5 Treg cells were significantly reduced in number and function soon after B cell depletion in the lymphoid tissues and pancreatic islets, before B cell regeneration. It should
be noted that when we used a shorter B cell depletion protocol, similar to the protocol we used in the previous study (4), we found comparable but less pronounced effects as described above (data not shown). However, when the majority of B cells had regenerated, regardless of which depletion protocol was used, the inflammatory phenotype of BDC2.5 T cells was reduced and the number and function of BDC2.5 Treg cells recovered. This is clear evidence that B cells regulate not only the pathogenic BDC2.5 CD4+ T cell immune responses, but that this effect may be mediated in part by an effect on Ag-specific Treg cells.

Immunoregulatory properties of subsets of B cells have been known for years (21–23). Recently there has been a focus on CD1d+ B cells as having immunoregulatory function (16, 17, 19, 24). Matsushita et al. (18) also reported that these CD1d+ B cells expressed CD5 and could suppress EAE and contact hypersensitivity (19). The regulation was mediated by IL-10 (19). In contrast to these findings, in our diabetes model, we showed that the CD1d+ B cell frequency was reduced in newly regenerated B cells and the CD1d+ B cells from the mice used in this study (BDC2.5NOD, 2H7-, or mlgG-treated hCD20-BDC2.5NOD and normal NOD mice) did not demonstrate regulatory effects on pathogenic BDC2.5 T cells in vitro and in vivo, compared with CD1d-B cells, although CD1d+CD5+ B cells showed some suppression in vitro. In addition, the suppression was independent of IL-10 but dependent on cell–cell contact. We suggest that there may be at least two factors that account for these differences. First, there are genetic differences in the mouse strains namely C57BL/6 versus NOD mice. Compared with the C57BL/6 mice used in the previous studies, NOD mice have differences in function of APCs, NK cells, Treg cells and deficiency of complement C5 (25–27). Second, there are differences in the type of autoimmune disease model used—immunization-induced disease versus spontaneous disease; immunization induced EAE is a very different autoimmune disease model from the NOD mice that develop spontaneous T1D. It is clear that more studies are required to further understand the differences in Breg cells in different disease models and whether immunoregulatory cytokine(s) are involved in the function of Breg cells in our model presented in this study.

In summary, using an islet Ag-specific T cell model system, we have found that following B cell depletion, diabetogenic T cells were more aggressive; however, this aggressive phenotype was diminished after B cell repopulation. Thus, there may be a biphasic response to B cell depletion—exacerbation of diabetogenic T cell activity, followed by increased regulation, which may help to explain why more complete protection is not achieved with B cell depletion later on in the course of disease. It is important to note that our current study extends our previous findings where we investigated immune regulation long after B cell repopulation (4). In the current study, we also identified a CD1d+ B cell subset that showed strong immunoregulatory function, which was independent of IL-10 but dependent on cell–cell contact. Our results suggest that anti-CD20 treatment increases B cell regulation of pathogenic Ag-specific T cells and enhances Treg cells, particularly after B cell regeneration and one of the beneficial effects of rituximab therapy likely lies in the postregeneration period. Thus, we suggest that the shortest possible B cell depletion period should be considered such that the period of increased pathogenicity of Ag-specific T cells should be minimized and reinforces the notion that the recovery phase after B cell depletion leads to increased regulation and the therapeutic benefits of this treatment. It will be necessary to take this into account in the design of future clinical protocols.

